[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642827":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":29,"locations":35,"responsibleParty":81,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":28,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":28,"enrollmentInfo":96,"targetDuration":28,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":108,"overallStatus":38,"whyStopped":28,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"Cellio Therapeutics Inc","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1","EXPERIMENTAL","C.001Low Dose",[13],"Biological: Injection",{"label":15,"type":10,"description":16,"interventionNames":17},"Arm 2","C.001 Medium Dose",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arm 3","C.001 High Dose",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"BIOLOGICAL","Injection","C.001 administered once via subretinal injection",[9,15,19],null,[30],{"name":31,"role":32,"phone":33,"phoneExt":28,"email":34},"Clinical Trial Administrator","CONTACT","999-999-9999","trials@celliotherapeutics.com",[36,54,68],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Retina Vision Consultants","RECRUITING","Beverly Hills","California","90210","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-118.40036,34.07362,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":28,"email":34},"Pradeep Prasad, MD","(310) 269-8565",{"facility":55,"status":56,"city":57,"state":40,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Palo Alto Medical Foundation","NOT_YET_RECRUITING","Palo Alto","94301",{"type":45,"coordinates":60},[61,62],-122.14302,37.44188,{"lat":62,"lon":61},[65],{"name":66,"role":32,"phone":67,"phoneExt":28,"email":34},"Ehsan Rahimy, MD","(650) 853-2974",{"facility":69,"status":56,"city":70,"state":40,"zip":71,"country":42,"countryCode":43,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Retinal Consultants Medical Group","Sacramento","95825",{"type":45,"coordinates":73},[74,75],-121.4944,38.58157,{"lat":75,"lon":74},[78],{"name":79,"role":32,"phone":80,"phoneExt":28,"email":34},"David Telander, MD","(916) 454-4861",{"type":82,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR",[84],{"name":85,"class":86},"California Institute for Regenerative Medicine (CIRM)","OTHER","100642827","phase-1-study-of-c001-in-retinal-degeneration-100642827",false,"NCT07594236","Phase 1 Study of C.001 in Retinal Degeneration","A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of retinal disease associated with retinal pigment epithelium degeneration (e.g., geographic atrophy or Stargardt disease)\n* Visual acuity within protocol-defined limits\n* Stable ocular condition prior to enrollment\n* Medically suitable for ophthalmic surgery and anesthesia\n* Willingness to comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Active or prior choroidal neovascularization (CNV)\n* Recent myocardial infarction or significant uncontrolled cardiovascular disease\n* Uncontrolled glaucoma\n* Significant ocular inflammatory disease\n* Recent intraocular surgery within protocol-defined timeframe\n* Active systemic infection\n* Poorly controlled diabetes (e.g., HbA1c \\>8.5%)\n* Participation in another investigational study within 3 months prior to screening","ALL","18 Years",{"count":97,"type":98},15,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","This is a first-in-human Phase 1 study evaluating the safety and tolerability of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium.\n\nParticipants will receive a single administration of C.001 delivered by subretinal injection. The study will evaluate three dose levels in a sequential manner.\n\nThe primary objective is to assess the safety of C.001 over a 3-month period following administration. Participants will be followed for up to 12 months to further evaluate safety and explore changes in visual function and retinal structure.",[104,105,106,107],"Geographic Atrophy","Stargardt Disease","RPE-mediated Maculopathy","Age Related Macular Degeneration",[109,110,111],"macular degeneration","macular distrophy","C.001","2026-08-14",{"date":114,"type":115},"2026-08-17","ACTUAL",{"date":117,"type":115},"2026-04-07",{"date":119,"type":98},"2029-12-31",{"name":5,"class":6},3]